Key result
Adding DRSP/E2 to enalapril in hypertensive postmenopausal women significantly reduced 24-h ambulatory systolic (-9 mm Hg, P=0.014) and diastolic (-5 mm Hg, P=0.007) blood pressure versus placebo.
Why the study?
Does drospirenone/17-beta-estradiol reduce 24-hour ambulatory blood pressure in hypertensive postmenopausal women receiving enalapril?
Population
24 nonsmoking postmenopausal women with hypertension, receiving enalapril maleate 10 mg twice a day
Comparison
Drospirenone/17-beta-estradiol added to… vs Matching placebo added to enalapril maleate for…
Design
RCT, Randomized, two-parallel group, Double-blind
Follow-up
14 days
Authors
Loading...
Supports adding DRSP/E2 to enalapril for better BP control in hypertensive postmenopausal women; extends evidence for its antimineralocorticoid effects in combination therapy.
RCT (n=24)
Double-blind
randomized
Does drospirenone/17-beta-estradiol reduce 24-hour ambulatory blood pressure in hypertensive postmenopausal women receiving enalapril?
p-value: p=0.014
Drospirenone/17-beta-estradiol provides a significant additive blood pressure-lowering effect when combined with enalapril in hypertensive postmenopausal women, consistent with an antimineralocorticoid effect.
Preston et al. (2002) conducted an RCT in hypertension (n=24). DRSP/17beta-estradiol (DRSP/E2) vs. Placebo was evaluated on 24-h ambulatory systolic blood pressure (p=0.014). Adding DRSP/E2 to enalapril in hypertensive postmenopausal women significantly reduced 24-h ambulatory systolic (-9 mm Hg, P=0.014) and diastolic (-5 mm Hg, P=0.007) blood pressure versus placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: